7154 An International Expanded Access Program (EAP) of RAD001 (everolimus) in patients with metastatic renal cell carcinoma (mRCC) who fail, or become intolerant of a prior vascular endothelial growth factor receptor (VEGFr) therapy

V Grünwald,S.Y Rah,K Miller,P.I Karakiewicz,J.P Machiels,J.J Hajdenberg,B.I Rini,M Rosamilia,D Resta,S.H Lee

doi:10.1016/s1359-6349(09)71487-9

7154 An International Expanded Access Program (EAP) of RAD001 (everolimus) in patients with metastatic renal cell carcinoma (mRCC) who fail, or become intolerant of a prior vascular endothelial growth factor receptor (VEGFr) therapy

V Grünwald, S.Y Rah + Show 8 more

https://doi.org/10.1016/s1359-6349(09)71487-9

Copy DOI

Journal: EJC Supplements	Publication Date: Sep 1, 2009
Citations: 1

#Prior Vascular Endothelial Growth Factor #Vascular Endothelial Growth Factor Receptor + Show 8 more

Abstract
Full-Text
Similar Papers

Abstract

7154 An International Expanded Access Program (EAP) of RAD001 (everolimus) in patients with metastatic renal cell carcinoma (mRCC) who fail, or become intolerant of a prior vascular endothelial growth factor receptor (VEGFr) therapy

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: EJC Supplements

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.